PDB59 LIXISENATIDE, BASAL INSULIN AND PREMIXED INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY ORAL ANTIDIABETIC DRUGS: NETWORK META-ANALYSIS AND COST-EFFECTIVENESS ANALYSIS

P. Men,S. Qu,C. Li,S. Zhai

DOI: https://doi.org/10.1016/j.jval.2019.04.608

IF: 5.156

2019-01-01

Value in Health

Abstract:To compare the efficacy, safety and long-term cost-effectiveness of lixisenatide 20 ug once daily (Lixisenatide) versus basal insulin (BI) and premixed insulin (Premix) once daily for patients with type 2 diabetes mellitus (T2DM) inadequately controlled by oral antidiabetic drugs (OADs) in China. A systematic literature review was conducted in PubMed, Cochrane Library, CNKI, and WanFang database up to July 2018. The network meta-analysis (NMA) was applied to calculate the relative risk (RR) or mean difference (MD) with 95% credibility interval (95%Crl) within a Bayesian framework. The IQVIA CORE Diabetes model was used to estimate the quality-adjusted life-years (QALYs), direct medical costs and incremental cost-effectiveness ratios (ICERs) from the perspective of China healthcare system. Eleven randomized controlled trials involving 4,511 patients were included in the NMA. There is no significant difference in the HbA1c reduction comparing Lixisenatide with BI (MD=0.27%, 95%Crl: -0.02%, 0.57%) and Premix (MD=0.32%, 95%Crl: -0.01%, 0.66%). Lixisenatide was associated with a statistically significant reduction in the body weight versus BI (MD=-3.22kg, 95% CrI: -5.51kg to -0.94kg) and Premix (MD=-2.68kg, 95%CrI: -5.16kg to -0.20kg). The incidence of symptomatic hypoglycemia was significantly lower for Lixisenatide compared with BI (RR=0.22, 95% CrI: 0.09 to 0.52) and Premix (RR=0.17, 95% CrI: 0.07 to 0.41). The cost-effectiveness analysis indicated that assuming the willingness-to-pay threshold was set at 3 times GDP per capita per QALY in China (RMB 178,980), Lixisenatide was a cost-effective option with ICERs of RMB 72,492/QALY and RMB 140,830/QALY gained versus BI and Premix, respectively. For T2DM patients inadequately controlled by OADs, Lixisenatideis is associated with significantly decreased body weight and lower risk of symptomatic hypoglycemia compared with BI and Premix, accompanied by a similar HbA1c reduction. It is a cost-effective treatment alternative in China.